EMPA-Kidney Seals SGLT2 Inhibitors as ' Foundational ' for CKD EMPA-Kidney Seals SGLT2 Inhibitors as ' Foundational ' for CKD
Empagliflozin ' s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.Medscape Medical News
Source: Medscape Pulmonary Medicine Headlines - Category: Respiratory Medicine Tags: Nephrology News Source Type: news
More News: Chronic Kidney Disease | Diabetes | Empagliflozin | Endocrinology | Jardiance | Respiratory Medicine | SGLT2 Inhibitors | Urology & Nephrology